Middlebrook Pharmaceuticals (MBRK) Inactive 10-Q2006 Q1 Quarterly report

Filed: 12 May 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: added, agenda, appointment, beneficial, Bulletin, calculating, cancellation, cancelled, carefully, cephalosporin, Code, committee, complex, concurrently, deem, demand, diversity, earliest, eligible, exceed, facing, February, fifteenth, filled, Food, forecast, foreign, guidance, headcount, incentive, ingredient, input, inspection, inventory, IssueNo, Item, lab, minimal, NDA, nonemployee, nonvested, obsolete, ofRegulation, onForm, opportunity, original, Patheon, payroll, permitted, pharmacokinetic, pharmacy, postponed, prescribed, profile, publicly, raw, redesigned, refine, rehired, rehiring, requisite, respiratory, satisfy, Section, shelf, shorter, skin, sNDA, strong, structure, submitted, subsidiary, substitution, supplemental, thisForm, toForm, tract, transferred, travel, uncomplicated, unrecognized, unused, upper, vendor, volume, write

Removed: Abbott, Additionally, base, begin, Biaxin, bioequivalence, broad, clarithromycin, closing, competing, consulting, country, customer, diligence, discontinue, discontinued, distributor, earlier, emergence, enhanced, exceeded, expended, extended, failing, fully, generated, GSK, history, implement, investigator, laboratory, licensed, noncash, obtained, passed, patient, pay, pivotal, produce, promotion, pursue, quoted, redirection, Regulation, reimbursed, release, reliably, representative, restatement, retroactive, SEC, seller, separate, shared, sprinkle, substantially, tablet, transaction, utilize, whichever, XL

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

MBRK similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

Certification of Principal Financial Officer
Pursuant to 18 U.S.C. 1350
(Section 906 of the Sarbanes-Oxley Act of 2002)

I, Robert C. Low, Vice President, Finance and Acting Chief Financial Officer (principal financial officer) of Advancis Pharmaceutical Corporation (the “Registrant”), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended March 31, 2005 of the Registrant (the “Report”), that:

(1) The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.


/s/ ROBERT C. LOW Name: Robert C. Low Date: May 12, 2006